ES2822375T3 - Preparación de la forma no cristalina del ácido obeticólico - Google Patents
Preparación de la forma no cristalina del ácido obeticólico Download PDFInfo
- Publication number
- ES2822375T3 ES2822375T3 ES17202916T ES17202916T ES2822375T3 ES 2822375 T3 ES2822375 T3 ES 2822375T3 ES 17202916 T ES17202916 T ES 17202916T ES 17202916 T ES17202916 T ES 17202916T ES 2822375 T3 ES2822375 T3 ES 2822375T3
- Authority
- ES
- Spain
- Prior art keywords
- acid
- obeticholic acid
- keto
- hydroxy
- cholan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 title claims abstract description 483
- 229960001601 obeticholic acid Drugs 0.000 title claims abstract description 386
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 174
- 239000000203 mixture Substances 0.000 claims abstract description 129
- 239000002253 acid Substances 0.000 claims abstract description 94
- 230000008569 process Effects 0.000 claims abstract description 73
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims abstract description 60
- 238000006243 chemical reaction Methods 0.000 claims abstract description 60
- 238000004821 distillation Methods 0.000 claims abstract description 23
- 238000001035 drying Methods 0.000 claims abstract description 19
- 239000012074 organic phase Substances 0.000 claims abstract description 19
- 229910000033 sodium borohydride Inorganic materials 0.000 claims abstract description 19
- 239000012279 sodium borohydride Substances 0.000 claims abstract description 19
- 239000007864 aqueous solution Substances 0.000 claims abstract description 18
- 238000001816 cooling Methods 0.000 claims abstract description 16
- 238000002425 crystallisation Methods 0.000 claims abstract description 13
- 230000008025 crystallization Effects 0.000 claims abstract description 12
- 238000002955 isolation Methods 0.000 claims abstract description 7
- 238000010583 slow cooling Methods 0.000 claims abstract description 3
- 238000005406 washing Methods 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 189
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 77
- 150000004702 methyl esters Chemical class 0.000 claims description 57
- 239000011541 reaction mixture Substances 0.000 claims description 49
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000003880 polar aprotic solvent Substances 0.000 claims description 16
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 8
- 235000011149 sulphuric acid Nutrition 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 abstract description 22
- 238000000926 separation method Methods 0.000 abstract description 4
- LHSZAKRHUYJKIU-CNFLPKCYSA-N (4r)-4-[(3r,5s,6r,8s,9s,10s,13r,14s,17r)-6-ethyl-3-hydroxy-10,13-dimethyl-7-oxo-1,2,3,4,5,6,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]3[C@@H]1C(=O)[C@H](CC)[C@H]1[C@]2(C)CC[C@@H](O)C1 LHSZAKRHUYJKIU-CNFLPKCYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 127
- 229910001868 water Inorganic materials 0.000 description 127
- 150000001875 compounds Chemical class 0.000 description 100
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 93
- 238000009472 formulation Methods 0.000 description 82
- 239000000243 solution Substances 0.000 description 76
- 239000000523 sample Substances 0.000 description 67
- 235000011121 sodium hydroxide Nutrition 0.000 description 61
- 239000000463 material Substances 0.000 description 52
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 49
- 229940125898 compound 5 Drugs 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 34
- 239000000047 product Substances 0.000 description 34
- 239000002904 solvent Substances 0.000 description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- 201000010099 disease Diseases 0.000 description 31
- 239000007787 solid Substances 0.000 description 31
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 30
- 235000019439 ethyl acetate Nutrition 0.000 description 29
- 238000000113 differential scanning calorimetry Methods 0.000 description 28
- 238000002411 thermogravimetry Methods 0.000 description 28
- 239000011248 coating agent Substances 0.000 description 27
- 238000000576 coating method Methods 0.000 description 27
- 238000000634 powder X-ray diffraction Methods 0.000 description 27
- 150000002148 esters Chemical class 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 239000012453 solvate Substances 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 239000012535 impurity Substances 0.000 description 23
- 239000010410 layer Substances 0.000 description 23
- 239000000725 suspension Substances 0.000 description 22
- 239000013078 crystal Substances 0.000 description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 21
- 239000012071 phase Substances 0.000 description 21
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 20
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- 239000008194 pharmaceutical composition Substances 0.000 description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 239000003826 tablet Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 238000002441 X-ray diffraction Methods 0.000 description 15
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 15
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 15
- 238000002844 melting Methods 0.000 description 15
- 230000008018 melting Effects 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 238000010626 work up procedure Methods 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000001179 sorption measurement Methods 0.000 description 14
- 208000016261 weight loss Diseases 0.000 description 14
- 230000004580 weight loss Effects 0.000 description 14
- -1 C-24 carboxylic acid Chemical class 0.000 description 13
- 239000008346 aqueous phase Substances 0.000 description 13
- 230000001587 cholestatic effect Effects 0.000 description 13
- 230000009477 glass transition Effects 0.000 description 13
- 238000001228 spectrum Methods 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 229940126214 compound 3 Drugs 0.000 description 12
- 238000013480 data collection Methods 0.000 description 12
- 238000005984 hydrogenation reaction Methods 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 12
- 229910015900 BF3 Inorganic materials 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 238000012512 characterization method Methods 0.000 description 11
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 238000006317 isomerization reaction Methods 0.000 description 10
- 238000005292 vacuum distillation Methods 0.000 description 10
- DXOCDBGWDZAYRQ-UHFFFAOYSA-N (3alpha,5beta)-3-Hydroxy-7-oxocholan-24 -oic acid Natural products C1CC(O)CC2CC(=O)C3C4CCC(C(CCC(O)=O)C)C4(C)CCC3C21C DXOCDBGWDZAYRQ-UHFFFAOYSA-N 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 9
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 9
- 239000008108 microcrystalline cellulose Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 8
- DXOCDBGWDZAYRQ-AURDAFMXSA-N 7-oxolithocholic acid Chemical compound C1C[C@@H](O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)CC[C@@H]3[C@]21C DXOCDBGWDZAYRQ-AURDAFMXSA-N 0.000 description 8
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- 206010016654 Fibrosis Diseases 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical group [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 229940079832 sodium starch glycolate Drugs 0.000 description 8
- 229920003109 sodium starch glycolate Polymers 0.000 description 8
- 239000008109 sodium starch glycolate Substances 0.000 description 8
- 238000004448 titration Methods 0.000 description 8
- 0 C[C@](CCC(O)=O)[C@@](CC1)[C@@](C)(CC2)C1[C@]1C2C(C)(CCCC2)C2[C@@](*)C1* Chemical compound C[C@](CCC(O)=O)[C@@](CC1)[C@@](C)(CC2)C1[C@]1C2C(C)(CCCC2)C2[C@@](*)C1* 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 230000004761 fibrosis Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 238000001907 polarising light microscopy Methods 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 238000001752 temperature-resolved X-ray diffraction Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 238000010931 ester hydrolysis Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000004313 potentiometry Methods 0.000 description 6
- 238000010926 purge Methods 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000008399 tap water Substances 0.000 description 6
- 235000020679 tap water Nutrition 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000007704 transition Effects 0.000 description 6
- 229910002483 Cu Ka Inorganic materials 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 235000017284 Pometia pinnata Nutrition 0.000 description 5
- 240000007653 Pometia tomentosa Species 0.000 description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 239000003637 basic solution Substances 0.000 description 5
- 210000000013 bile duct Anatomy 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 235000011007 phosphoric acid Nutrition 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102000004008 5'-Nucleotidase Human genes 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 4
- 206010008635 Cholestasis Diseases 0.000 description 4
- 206010010317 Congenital absence of bile ducts Diseases 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 238000003109 Karl Fischer titration Methods 0.000 description 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 201000005271 biliary atresia Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- HZBAVWLZSLOCFR-UHFFFAOYSA-N oxosilane Chemical compound [SiH2]=O HZBAVWLZSLOCFR-UHFFFAOYSA-N 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000002076 thermal analysis method Methods 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 4
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- KPRGOTLNGIBVFL-GINZOMEDSA-N 7-ketodehydroepiandrosterone Chemical group C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C(=O)C=C21 KPRGOTLNGIBVFL-GINZOMEDSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- 206010072877 Intestinal fibrosis Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000007870 cholestasis Effects 0.000 description 3
- 231100000359 cholestasis Toxicity 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 229910052593 corundum Inorganic materials 0.000 description 3
- 239000010431 corundum Substances 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 229910052738 indium Inorganic materials 0.000 description 3
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001757 thermogravimetry curve Methods 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010023421 Kidney fibrosis Diseases 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000007171 acid catalysis Methods 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012042 active reagent Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000005882 aldol condensation reaction Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 210000001953 common bile duct Anatomy 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000003869 coulometry Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000007416 differential thermogravimetric analysis Methods 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 230000010235 enterohepatic circulation Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 208000009866 extrahepatic cholestasis Diseases 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000011872 intimate mixture Substances 0.000 description 2
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 2
- 230000007872 intrahepatic cholestasis Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 230000001035 methylating effect Effects 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 235000021476 total parenteral nutrition Nutrition 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- 229910000809 Alumel Inorganic materials 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000015163 Biliary Tract disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- LHSZAKRHUYJKIU-SGDUQGPESA-N CC[C@H](C(C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)C3[C@H](C)CCC(O)=O)C2=O Chemical compound CC[C@H](C(C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)C3[C@H](C)CCC(O)=O)C2=O LHSZAKRHUYJKIU-SGDUQGPESA-N 0.000 description 1
- ZXERDUOLZKYMJM-ZHPZNHRVSA-N CC[C@H](C(C[C@@H](CC1)O)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC3)[C@@]1(C)[C@H]3C(C)CCC(O)=O)[C@H]2O Chemical compound CC[C@H](C(C[C@@H](CC1)O)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC3)[C@@]1(C)[C@H]3C(C)CCC(O)=O)[C@H]2O ZXERDUOLZKYMJM-ZHPZNHRVSA-N 0.000 description 1
- DFVDSLBYVWPKLJ-SPOAJKJNSA-N C[C@H](CCC(O)=O)C(CC1)[C@@](C)(CCC2[C@@](C)(CCCC3)C3C3)C1=C2C3O Chemical compound C[C@H](CCC(O)=O)C(CC1)[C@@](C)(CCC2[C@@](C)(CCCC3)C3C3)C1=C2C3O DFVDSLBYVWPKLJ-SPOAJKJNSA-N 0.000 description 1
- JFJUUQAZNPOYBK-VGBDVBKPSA-N C[C@](CC[C@@H](C1)[C@@](C)(CCC(O)=C2)C2/C2=C\C)([C@@H](CC3)C1C2=O)/C3=C(\C)/CCC(OC)=O Chemical compound C[C@](CC[C@@H](C1)[C@@](C)(CCC(O)=C2)C2/C2=C\C)([C@@H](CC3)C1C2=O)/C3=C(\C)/CCC(OC)=O JFJUUQAZNPOYBK-VGBDVBKPSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 1
- 239000005046 Chlorosilane Substances 0.000 description 1
- 206010049055 Cholestasis of pregnancy Diseases 0.000 description 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010013530 Diverticula Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 206010072104 Fructose intolerance Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000024815 Granulomatous liver disease Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 206010019878 Hereditary fructose intolerance Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 239000004594 Masterbatch (MB) Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033635 Pancreatic pseudocyst Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000030601 Parasitic Liver disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000009454 Portal vein thrombosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 231100000839 Vanishing bile duct syndrome Toxicity 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000004525 Zellweger Syndrome Diseases 0.000 description 1
- 208000036813 Zellweger spectrum disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- MEMUCXUKCBNISQ-UHFFFAOYSA-N acetonitrile;trifluoroborane Chemical group CC#N.FB(F)F MEMUCXUKCBNISQ-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000013477 bayesian statistics method Methods 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 201000006846 hereditary fructose intolerance syndrome Diseases 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 208000006663 kernicterus Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 208000008275 microscopic colitis Diseases 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- NUJGJRNETVAIRJ-PPJXEINESA-N octanal Chemical compound CCCCCCC[14CH]=O NUJGJRNETVAIRJ-PPJXEINESA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 238000003918 potentiometric titration Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 208000023021 right upper quadrant abdominal pain Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 201000011296 tyrosinemia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661531P | 2012-06-19 | 2012-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2822375T3 true ES2822375T3 (es) | 2021-04-30 |
Family
ID=48741553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17202916T Active ES2822375T3 (es) | 2012-06-19 | 2013-06-17 | Preparación de la forma no cristalina del ácido obeticólico |
Country Status (25)
| Country | Link |
|---|---|
| US (9) | US9238673B2 (enExample) |
| EP (4) | EP3992201A1 (enExample) |
| JP (6) | JP2015521621A (enExample) |
| KR (4) | KR20180083966A (enExample) |
| CN (2) | CN111228278A (enExample) |
| AU (5) | AU2013277429B2 (enExample) |
| BR (2) | BR112014031828B1 (enExample) |
| CA (3) | CA2877122C (enExample) |
| CL (2) | CL2014003475A1 (enExample) |
| CO (1) | CO7240414A2 (enExample) |
| DK (1) | DK3336097T3 (enExample) |
| EA (2) | EA032347B1 (enExample) |
| ES (1) | ES2822375T3 (enExample) |
| HK (1) | HK1211296A1 (enExample) |
| IL (3) | IL236231A0 (enExample) |
| IN (1) | IN2014MN02561A (enExample) |
| MX (2) | MX365059B (enExample) |
| NZ (3) | NZ703072A (enExample) |
| PH (1) | PH12014502835A1 (enExample) |
| PL (1) | PL3336097T3 (enExample) |
| PT (1) | PT3336097T (enExample) |
| SG (3) | SG11201408501UA (enExample) |
| SI (1) | SI3336097T1 (enExample) |
| TW (1) | TWI673284B (enExample) |
| WO (1) | WO2013192097A1 (enExample) |
Families Citing this family (171)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138390B2 (en) | 2001-03-12 | 2006-11-21 | Intercept Pharmaceuticals | Steroids as agonists for FXR |
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| ES2822375T3 (es) | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
| US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
| KR102106186B1 (ko) * | 2012-11-28 | 2020-05-04 | 인터셉트 파마슈티컬즈, 인크. | 폐 질환의 치료 |
| US9814733B2 (en) * | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| WO2014169832A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| MX362543B (es) | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| HRP20210610T1 (hr) | 2013-07-19 | 2021-05-28 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihove uporabe |
| PT3035940T (pt) | 2013-08-23 | 2019-01-28 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
| EP3149156B1 (en) | 2014-05-28 | 2021-02-17 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| ES2938874T3 (es) | 2014-05-29 | 2023-04-17 | Bar Pharmaceuticals S R L | Derivados de colano para su uso en el tratamiento y/o prevención de enfermedades mediadas por FXR y TGR5/GPBAR1 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN106459136B (zh) * | 2014-09-28 | 2018-06-26 | 江苏盛迪医药有限公司 | 一种奥贝胆酸的制备方法 |
| EP3885352B1 (en) | 2014-10-16 | 2024-11-27 | Sage Therapeutics, Inc. | A compound, compositions thereof and this compound for use in methods of treating cns disorders |
| EP4275748A3 (en) | 2014-10-16 | 2024-01-03 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| JP6804438B2 (ja) | 2014-10-17 | 2020-12-23 | チルドレンズ ホスピタル メディカル センター | 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法 |
| CA2966885A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| CN107108688B (zh) * | 2014-11-19 | 2019-10-29 | Nzp英国有限公司 | 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇 |
| EA033603B1 (ru) | 2014-11-19 | 2019-11-08 | Nzp Uk Ltd | 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| TWI686400B (zh) | 2014-11-19 | 2020-03-01 | 英商Ｎｚｐ英國有限公司 | 化合物（二） |
| MX375863B (es) | 2014-11-19 | 2025-03-07 | Nzp Uk Ltd | Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr) |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| HK1244708A1 (zh) | 2014-11-26 | 2018-08-17 | 英安塔制药有限公司 | 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法 |
| RS60343B1 (sr) | 2014-11-27 | 2020-07-31 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns-a |
| CN105777835B (zh) * | 2014-12-25 | 2020-02-14 | 重庆药友制药有限责任公司 | 一种制备鹅去氧胆酸类似物的方法 |
| CN105801653B (zh) | 2014-12-30 | 2018-04-17 | 苏州晶云药物科技有限公司 | 奥贝胆酸的晶型a及其制备方法 |
| CN105859814A (zh) * | 2015-01-23 | 2016-08-17 | 江苏奥赛康药业股份有限公司 | 一种奥贝胆酸化合物及其药物组合物 |
| SMT202100113T1 (it) | 2015-01-26 | 2021-05-07 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| ES2905872T3 (es) | 2015-02-06 | 2022-04-12 | Intercept Pharmaceuticals Inc | Composiciones farmacéuticas para terapia combinada |
| RU2017130466A (ru) | 2015-02-11 | 2019-03-12 | Энанта Фармасьютикалс, Инк. | Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения |
| CN105985395A (zh) * | 2015-02-13 | 2016-10-05 | 江苏奥赛康药业股份有限公司 | 一种奥贝胆酸化合物及含有该化合物的药物组合物 |
| CN105985396A (zh) * | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| EP3258939B1 (en) | 2015-02-20 | 2022-09-07 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| KR20170125927A (ko) * | 2015-03-09 | 2017-11-15 | 인터셉트 파마슈티컬즈, 인크. | 골밀도의 조절 방법 |
| NZ735126A (en) | 2015-03-31 | 2022-10-28 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| CN107613986A (zh) | 2015-04-07 | 2018-01-19 | 英特塞普特医药品公司 | 用于组合疗法的药物组合物 |
| CN105777836A (zh) * | 2015-04-09 | 2016-07-20 | 厦门蔚扬药业有限公司 | 奥贝胆酸的多晶型物及其制备方法 |
| WO2016168553A1 (en) * | 2015-04-17 | 2016-10-20 | Concert Pharmaceuticals, Inc. | Deuterated obeticholic acid |
| PE20180690A1 (es) * | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| CN106290594B (zh) * | 2015-05-27 | 2020-07-17 | 中美华世通生物医药科技（武汉）有限公司 | 测定奥贝胆酸片溶出含量的方法 |
| CN105294801A (zh) * | 2015-07-02 | 2016-02-03 | 扬子江药业集团南京海陵药业有限公司 | 6-乙基鹅去氧胆酸异构体的合成及其分离测定方法 |
| CZ2015504A3 (cs) | 2015-07-16 | 2017-01-25 | Zentiva, K.S. | Krystalické formy obeticholové kyseliny |
| EP3124080A1 (en) * | 2015-07-28 | 2017-02-01 | Merz Pharma GmbH & Co. KGaA | Semisynthetic bile acids for injection lipolysis |
| CN105085597B (zh) * | 2015-08-28 | 2017-03-29 | 成都百裕制药股份有限公司 | 一种无定型奥贝胆酸的制备方法 |
| CN106478756A (zh) * | 2015-09-02 | 2017-03-08 | 中美华世通生物医药科技（武汉）有限公司 | Oca-e单晶及其制备方法和用途 |
| CA2998876A1 (en) * | 2015-09-21 | 2017-03-30 | Intercept Pharmaceuticals, Inc. | Methods of promoting hepatic regeneration |
| KR20180052756A (ko) | 2015-09-24 | 2018-05-18 | 인터셉트 파마슈티컬즈, 인크. | 담즙산 유도체 제조를 위한 방법 및 중간체 |
| TN2018000106A1 (en) | 2015-10-07 | 2019-10-04 | Intercept Pharmaceuticals Inc | Farnesoid x receptor modulators |
| CN106589038A (zh) * | 2015-10-15 | 2017-04-26 | 重庆医药工业研究院有限责任公司 | 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法 |
| CN106589039B (zh) * | 2015-10-15 | 2019-12-17 | 苏州朗科生物技术股份有限公司 | 一种奥贝胆酸的制备方法及相关化合物 |
| CN106632564B (zh) * | 2015-10-30 | 2021-04-13 | 苏州泽璟生物制药股份有限公司 | 奥贝胆酸盐及其无定形物和药物组合物 |
| CN106668027A (zh) * | 2015-11-05 | 2017-05-17 | 中美华世通生物医药科技（武汉）有限公司 | 奥贝胆酸药物组合物及其制备方法 |
| CA3004275A1 (en) * | 2015-11-06 | 2017-05-11 | Intercept Pharmaceuticals, Inc. | Methods for the preparation of obeticholic acid and derivatives thereof |
| CN106749466B (zh) * | 2015-11-23 | 2019-05-21 | 南京济群医药科技股份有限公司 | 一种高纯度奥贝胆酸的制备方法 |
| CN105315320B (zh) * | 2015-11-30 | 2017-03-08 | 山东省药学科学院 | 一种制备奥贝胆酸的方法 |
| CN106810586A (zh) * | 2015-12-01 | 2017-06-09 | 中美华世通生物医药科技（武汉）有限公司 | 奥贝胆酸晶型ⅱ及其制备方法和用途 |
| CN106810587A (zh) * | 2015-12-01 | 2017-06-09 | 中美华世通生物医药科技（武汉）有限公司 | 制备无定型奥贝胆酸的方法 |
| CN106822005A (zh) * | 2015-12-03 | 2017-06-13 | 江苏先声药业有限公司 | 奥贝胆酸组合物及其制备方法 |
| CN106854229A (zh) * | 2015-12-08 | 2017-06-16 | 陈剑 | 一类脂肪酸盐,其制备及其在医药上的应用 |
| CN105481925B (zh) * | 2015-12-17 | 2018-06-22 | 南京济群医药科技股份有限公司 | 一种奥贝胆酸及其中间体的制备方法 |
| EA201891491A1 (ru) * | 2015-12-22 | 2018-11-30 | Интерсепт Фармасьютикалз, Инк. | Полиморфные кристаллические формы обетихолевой кислоты |
| CN105399793A (zh) * | 2015-12-24 | 2016-03-16 | 北京康立生医药技术开发有限公司 | 一种胆烷酸的制备方法 |
| CN106916195A (zh) * | 2015-12-25 | 2017-07-04 | 中美华世通生物医药科技（武汉）有限公司 | 奥贝胆酸中间体的纯化方法 |
| WO2017115324A1 (en) | 2016-01-01 | 2017-07-06 | Lupin Limited | Solid forms of obeticholic acid and processes thereof |
| CN105566429B (zh) * | 2016-01-22 | 2020-12-01 | 南京长澳医药科技有限公司 | 一种奥贝胆酸1型的制备方法 |
| CN105646633B (zh) * | 2016-01-22 | 2020-05-26 | 南京长澳医药科技有限公司 | 一种制备奥贝胆酸1型的方法 |
| CN105646634A (zh) * | 2016-01-29 | 2016-06-08 | 中国药科大学 | 奥贝胆酸杂质的制备方法 |
| CN108541255B (zh) | 2016-02-02 | 2019-06-14 | 深圳市塔吉瑞生物医药有限公司 | 一种甾体类化合物及包含该化合物的组合物及其用途 |
| KR102851614B1 (ko) * | 2016-02-04 | 2025-08-29 | 신돔 파마, 인크. | 장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법 |
| CN108779141A (zh) * | 2016-02-10 | 2018-11-09 | 雷迪博士实验室有限公司 | 奥贝胆酸的胺盐 |
| US10323061B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| WO2017147159A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| CN107126419B (zh) * | 2016-02-26 | 2020-06-19 | 石药集团中诺药业（石家庄）有限公司 | 一种奥贝胆酸片剂及其制备方法 |
| CN106008639B (zh) * | 2016-03-11 | 2019-01-08 | 深圳市塔吉瑞生物医药有限公司 | 用于预防或治疗fxr-介导疾病的胆烷酸化合物 |
| CN107188917A (zh) * | 2016-03-15 | 2017-09-22 | 正大天晴药业集团股份有限公司 | 奥贝胆酸盐及其药物组合物 |
| CN105541953B (zh) * | 2016-03-15 | 2017-11-21 | 成都市新功生物科技有限公司 | 一种高纯度奥贝胆酸的重结晶纯化方法 |
| JPWO2017170434A1 (ja) * | 2016-03-28 | 2019-01-31 | インターセプト ファーマシューティカルズ， インコーポレイテッド | Ｆｘｒアゴニストとａｒｂの組み合わせ医薬 |
| US11413295B2 (en) | 2016-03-31 | 2022-08-16 | Intercept Pharmaceuticals, Inc. | Oral preparation of obeticholic acid |
| CN107531744B (zh) * | 2016-03-31 | 2020-03-13 | 江苏恒瑞医药股份有限公司 | 一种奥贝胆酸的新结晶形式及其制备方法 |
| ES2901598T3 (es) | 2016-03-31 | 2022-03-23 | Intercept Pharmaceuticals Inc | Comprimido recubierto con película que tiene una alta estabilidad química del ingrediente activo |
| EP3228306A1 (en) | 2016-04-04 | 2017-10-11 | ratiopharm GmbH | Complex compound comprising obeticholic acid and cyclodextrin and pharmaceutical formulation comprising the complex compound |
| WO2017174515A1 (en) | 2016-04-04 | 2017-10-12 | Dipharma Francis S.R.L. | Method for preparing a farnesoid x receptor agonist |
| TW201738254A (zh) * | 2016-04-19 | 2017-11-01 | 英特賽普醫藥品公司 | 奧貝膽酸及其衍生物之製備方法 |
| EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| CN105859817A (zh) * | 2016-05-09 | 2016-08-17 | 成都宇西医药技术有限公司 | 一种制备3α-羟基-6-乙烯基-7-酮基-5β-胆烷酸的方法 |
| CN107400154A (zh) * | 2016-05-18 | 2017-11-28 | 北京凯因科技股份有限公司 | 一种制备3α,7α-二-羟基-6α-乙基-5β-胆烷酸的方法 |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| CN106046094A (zh) * | 2016-05-30 | 2016-10-26 | 福建广生堂药业股份有限公司 | 一种奥贝胆酸二聚体杂质及其制备方法 |
| CN105859818A (zh) * | 2016-05-31 | 2016-08-17 | 四川瑞希康生物医药有限公司 | 一种奥贝胆酸α晶型及其制备方法、药物组合物和用途 |
| US10875887B2 (en) | 2016-06-01 | 2020-12-29 | Dr. Reddy's Laboratories Limited. | Process for preparation of obeticholic acid |
| CN105997909A (zh) * | 2016-06-02 | 2016-10-12 | 中国药科大学 | 一种奥贝胆酸口崩片及其制备方法 |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| SI3730487T1 (sl) | 2016-06-13 | 2022-08-31 | Gilead Sciences, Inc. | Azetidinski derivati kot modulatorji FXR (NR1H4) |
| CN106083971B (zh) * | 2016-06-17 | 2017-11-14 | 苏州敬业医药化工有限公司 | 一种(E)‑3α‑羟基‑6‑亚乙基‑7‑酮‑5β‑胆烷‑24‑酸的制备方法 |
| CZ2016385A3 (cs) | 2016-06-28 | 2018-01-10 | Zentiva, K.S. | Způsoby přípravy intermediátů pro syntézu Obeticholové kyseliny |
| CN107540720B (zh) * | 2016-06-29 | 2021-03-02 | 常州市第四制药厂有限公司 | 3α,7α-二羟基-6α-乙基-5β-胆烷酸晶型H及其制备方法和应用 |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| CN107648190B (zh) * | 2016-07-26 | 2021-04-27 | 海南先声药业有限公司 | 奥贝胆酸组合物及其制备方法 |
| CN106279331B (zh) * | 2016-07-27 | 2019-06-14 | 宋火良 | 胆酸类肝病治疗药物 |
| CN107674106B (zh) * | 2016-08-01 | 2021-06-22 | 华北制药集团新药研究开发有限责任公司 | 一种奥贝胆酸二聚体的制备方法 |
| CN106279335A (zh) * | 2016-08-12 | 2017-01-04 | 齐鲁制药有限公司 | 一种制备奥贝胆酸及其中间体的方法 |
| EP3287467A1 (en) | 2016-08-22 | 2018-02-28 | ratiopharm GmbH | Preparation of obeticholic acid comprising continuous flow process steps |
| CN107793463A (zh) * | 2016-08-29 | 2018-03-13 | 鲁南制药集团股份有限公司 | 一种3α‑羟基‑6α‑乙基‑7‑酮‑5β‑胆‑24‑酸的制备方法 |
| CN107778339A (zh) * | 2016-08-29 | 2018-03-09 | 鲁南制药集团股份有限公司 | 一种无定型奥贝胆酸的制备方法 |
| EP3293196A1 (en) | 2016-09-09 | 2018-03-14 | Hexal AG | Process for purifying obeticholic acid |
| CN106478757B (zh) * | 2016-09-27 | 2019-01-18 | 华南理工大学 | 一种3α,7α-二羟基-6α-乙基胆烷酸的制备方法 |
| WO2018064441A1 (en) * | 2016-09-30 | 2018-04-05 | Intercept Pharmaceuticals, Inc | Crystalline forms of a bile acid derivative |
| CN107976506B (zh) * | 2016-10-25 | 2020-05-12 | 成都弘达药业有限公司 | 一种奥贝胆酸有关物质的检测方法 |
| EP3534976A4 (en) | 2016-11-04 | 2020-09-16 | Children's Hospital Medical Center | PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE |
| WO2018102418A1 (en) * | 2016-11-29 | 2018-06-07 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| BR112019011740A2 (pt) * | 2016-12-09 | 2019-10-29 | Cadila Healthcare Limited | composição farmacêutica e método para o tratamento de colangite biliar primária |
| CN108614038B (zh) * | 2016-12-13 | 2022-05-17 | 亚宝药业集团股份有限公司 | 一种测定奥贝胆酸原料药有关物质的方法 |
| CN106749472B (zh) * | 2016-12-30 | 2019-02-22 | 江苏开元医药化工有限公司 | 一种3α-羟基-6α-乙基-7-酮-5β-胆烷-24-酸的制备方法 |
| CN106645497A (zh) * | 2017-01-03 | 2017-05-10 | 山东省药学科学院 | 一种奥贝胆酸及其制剂中有关物质的检测方法 |
| CA3050276A1 (en) | 2017-01-18 | 2018-07-26 | Tremco Incorporated | Structural bonding composite |
| US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
| CN106892954B (zh) * | 2017-02-23 | 2019-04-30 | 广州隽沐生物科技有限公司 | 奥贝胆酸的制备工艺 |
| CA3055540A1 (en) * | 2017-03-08 | 2018-09-13 | Intercept Pharmaceuticals, Inc | Crystalline forms of obeticholic acid |
| JP6906626B2 (ja) | 2017-03-28 | 2021-07-21 | ギリアード サイエンシーズ， インコーポレイテッド | 肝疾患を処置するための治療的組み合わせ |
| CN108659086A (zh) * | 2017-03-29 | 2018-10-16 | 杭州源昶医药科技有限公司 | 一种奥贝胆酸的合成方法 |
| CA3058754A1 (en) | 2017-04-07 | 2018-10-11 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonyl carbamate bile acid derivatives |
| EP3609997A4 (en) | 2017-04-14 | 2021-03-03 | Children's Hospital Medical Center | COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES |
| CN106986910A (zh) * | 2017-04-19 | 2017-07-28 | 成都百特万合医药科技有限公司 | 奥贝胆酸中间体的制备方法 |
| CN110799519B (zh) * | 2017-04-20 | 2023-02-28 | 大雄Bio株式会社 | 利用连续流动反应的胆汁酸衍生物的制备方法 |
| WO2018211413A1 (en) * | 2017-05-15 | 2018-11-22 | Dr. Reddy’S Laboratories Limited | Solid forms of obeticholic acid and process for preparation |
| CZ2017298A3 (cs) | 2017-05-26 | 2018-12-05 | Zentiva, K.S. | Amorfní formy obeticholové kyseliny |
| CN107286160A (zh) * | 2017-06-05 | 2017-10-24 | 毛佳婧 | 一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法 |
| US12478612B2 (en) | 2017-06-30 | 2025-11-25 | Cindome Pharma, Inc. | Deuterated domperidone compositions, methods, and preparation |
| KR20240125702A (ko) | 2017-06-30 | 2024-08-19 | 신돔 파마, 인크. | 중수소화 돔페리돈 조성물, 방법, 및 제조 |
| CN109280071A (zh) * | 2017-07-19 | 2019-01-29 | 东莞东阳光药物研发有限公司 | 奥贝胆酸的晶型及其制备方法 |
| CN111050772A (zh) | 2017-07-24 | 2020-04-21 | 英特塞普特医药品公司 | 同位素标记的胆汁酸衍生物 |
| KR20200026273A (ko) | 2017-08-03 | 2020-03-10 | (주)메디톡스 | 담즙산류를 제조하기 위한 방법 |
| CN107383139A (zh) * | 2017-08-09 | 2017-11-24 | 杭州和泽医药科技有限公司 | 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法 |
| CN109485687A (zh) * | 2017-09-12 | 2019-03-19 | 成都弘达药业有限公司 | 奥贝胆酸的晶型j及其制备方法 |
| EP3694603A4 (en) | 2017-10-10 | 2021-07-14 | Children's Hospital Medical Center | ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF |
| US10611793B1 (en) | 2017-11-27 | 2020-04-07 | Teva Czech Industries S.R.O. | Solid state forms of obeticholic acid salts |
| WO2019106043A1 (en) | 2017-11-29 | 2019-06-06 | Hexal Ag | Pharmaceutical composition comprising obeticholic acid |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| WO2019145977A1 (en) * | 2018-01-25 | 2019-08-01 | Msn Laboratories Private Limited, R&D Center | PROCESS FOR THE PREPARATION OF 3α,7α-DIHYDROXY6α-ETHYL-5β-CHOLAN-24-OIC ACID |
| CN108440629A (zh) * | 2018-03-16 | 2018-08-24 | 丽珠集团新北江制药股份有限公司 | 一种制备奥贝胆酸中间体及奥贝胆酸的方法 |
| WO2019197962A1 (en) * | 2018-04-09 | 2019-10-17 | Biophore India Pharmaceuticals Pvt. Ltd | Crystalline forms of (3α, 5β, 6α, 7α)-6-ethyl-3, 7-dihydroxycholan-24-oic acid (obeticholic acid) and processes thereof |
| CN110655550A (zh) * | 2018-06-29 | 2020-01-07 | 江苏海悦康医药科技有限公司 | (E)-3α-羟基-6-亚乙基-7-氧代-5β-胆甾烷-24-酸的制备方法 |
| CN108794558B (zh) * | 2018-07-03 | 2020-05-22 | 丽珠集团新北江制药股份有限公司 | 一种反应条件温和的奥贝胆酸制备方法 |
| KR102887406B1 (ko) | 2018-07-26 | 2025-11-19 | 칠드런즈 호스피탈 메디칼 센터 | 간-담도-췌장 조직 및 이를 제조하는 방법 |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| WO2020039449A1 (en) | 2018-08-24 | 2020-02-27 | Solara Active Pharma Sciences Limited | An improved process for the preparation of obeticholic acid and intermediates used in the process thereof |
| WO2020056158A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| JP2022506782A (ja) * | 2018-11-08 | 2022-01-17 | インターセプト ファーマシューティカルズ， インコーポレイテッド | オベチコール酸の使用方法 |
| CN109535217B (zh) * | 2018-11-13 | 2020-04-14 | 丽珠集团新北江制药股份有限公司 | 一种奥贝胆酸的精制方法 |
| US11225473B2 (en) | 2019-01-15 | 2022-01-18 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
| EP3927683A1 (en) | 2019-02-19 | 2021-12-29 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| WO2020243590A1 (en) | 2019-05-30 | 2020-12-03 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
| AR119047A1 (es) | 2019-05-31 | 2021-11-17 | Sage Therapeutics Inc | Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc |
| WO2021029656A1 (ko) * | 2019-08-14 | 2021-02-18 | 주식회사 바이오톡스텍 | 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물 |
| CN112824425B (zh) * | 2019-11-21 | 2023-10-03 | 成都西岭源药业有限公司 | 一种6-位烯基取代胆酸化合物及其制备方法和应用 |
| WO2021231539A1 (en) * | 2020-05-13 | 2021-11-18 | Children's Hospital Medical Center | Alleviation of liver injury by activating the signaling pathway mediated by farnesoid x receptor |
| WO2022051321A1 (en) | 2020-09-03 | 2022-03-10 | Coherus Biosciences, Inc. | Fixed dose combinations of chs-131 and a fxr agonist |
| KR102526452B1 (ko) * | 2020-10-28 | 2023-04-27 | (주)델로 | 관절 구조를 포함하는 토이 로봇 |
| CN114644670A (zh) * | 2020-12-17 | 2022-06-21 | 四川弘远药业有限公司 | 奥贝胆酸和对氨基苯甲酸的共晶及其制备方法 |
| CN114236027B (zh) * | 2021-12-22 | 2024-01-12 | 中山百灵生物技术股份有限公司 | 一种(E)-6-亚乙基-3α-羟基-7-酮基-5β-胆甾烷-24-酸的检测方法 |
| US12343351B2 (en) | 2022-03-25 | 2025-07-01 | Rutgers, The State University Of New Jersey | Pulmonary function treatment |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4072695A (en) | 1972-09-21 | 1978-02-07 | Intellectual Property Development Corporation | 3α,7α-Dihydroxy-cholanic acid derivatives |
| IT1137459B (it) * | 1981-04-14 | 1986-09-10 | Erregierre Spa | Prodesso per la preparazione di acido ursodeossicolico ad alta purezza |
| EP0101554B1 (en) | 1982-07-29 | 1986-10-15 | Lehner A.G. | New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same |
| IT1206112B (it) | 1983-04-29 | 1989-04-14 | Lehner Ag | Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche. |
| IT1212835B (it) | 1983-08-18 | 1989-11-30 | Lehner Ag | Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche. |
| US4892868A (en) | 1984-08-17 | 1990-01-09 | Gipharmex, S.P.A. | Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions |
| IT1196377B (it) | 1984-12-21 | 1988-11-16 | Lehner Ag | Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| IT1223313B (it) | 1987-10-20 | 1990-09-19 | Gipharmex Spa | Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono |
| JPH0320265A (ja) * | 1989-02-10 | 1991-01-29 | Meiji Seika Kaisha Ltd | アミノチアゾール酢酸誘導体並びにその製造法 |
| US5175320A (en) | 1989-04-17 | 1992-12-29 | Giuliani S.P.A. | Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
| IT1229570B (it) | 1989-04-17 | 1991-09-04 | Giuliani Spa | Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono. |
| DE69018592T2 (de) | 1989-12-13 | 1995-10-05 | Mitsubishi Chem Corp | Pyrazolylacrylsäure-Derivate, verwendbar als systemische Fungiziden in Pflanzen- und Materialschutz. |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| CA2260044A1 (en) | 1996-07-12 | 1998-01-22 | Stephen Alistair Smith | Novel treatment of leptine resistance |
| JP3600713B2 (ja) | 1997-08-06 | 2004-12-15 | 東京応化工業株式会社 | ポジ型ホトレジスト組成物 |
| US6008237A (en) | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
| ES2317688T3 (es) | 1998-01-29 | 2009-04-16 | Amgen Inc. | Moduladores ppar-gamma. |
| JP3146187B2 (ja) * | 1998-06-26 | 2001-03-12 | 高砂香料工業株式会社 | ジホスフィンオキシドの新規な製造方法 |
| JP2002528721A (ja) | 1998-10-23 | 2002-09-03 | グラクソ グループ リミテッド | 核内受容体のリガンド用のアッセイ |
| EP1140079B1 (en) | 1998-12-23 | 2009-06-03 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
| US6465258B1 (en) | 1999-01-07 | 2002-10-15 | Tularik, Inc. | FXR receptor-mediated modulation cholesterol metabolism |
| ATE330632T1 (de) | 1999-03-26 | 2006-07-15 | Hope City | Selektion von fxr-rezeptormodulatoren |
| EP1473042B1 (en) | 1999-03-26 | 2006-06-21 | City of Hope | Screening for FXR receptor modulators |
| US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
| US6906057B1 (en) | 1999-06-11 | 2005-06-14 | Allergan, Inc. | Methods for modulating FXR receptor activity |
| HK1047705A1 (zh) | 1999-06-11 | 2003-03-07 | Allergan, Inc. | 用於调节fxr受体活性的方法 |
| US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| WO2001030343A1 (en) | 1999-10-22 | 2001-05-03 | Merck & Co., Inc. | Pharmaceuticals for treating obesity |
| US6627636B2 (en) | 2000-06-15 | 2003-09-30 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| AU2001288623A1 (en) | 2000-09-05 | 2002-03-22 | Tularik, Inc. | Fxr modulators |
| US20020119958A1 (en) | 2001-02-13 | 2002-08-29 | Shinichiro Tojo | Therapeutic agent for hyperlipidemia |
| US7138390B2 (en) * | 2001-03-12 | 2006-11-21 | Intercept Pharmaceuticals | Steroids as agonists for FXR |
| EP1378749A4 (en) | 2001-04-12 | 2005-05-11 | Takeda Pharmaceutical | SCREENING METHOD |
| WO2003015777A1 (en) | 2001-08-13 | 2003-02-27 | Lion Bioscience Ag | Nr1h4 nuclear receptor binding compounds |
| DE60131967D1 (de) | 2001-08-13 | 2008-01-31 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| WO2003016280A1 (en) | 2001-08-13 | 2003-02-27 | Lion Bioscience Ag | Nr1h4 nuclear receptor binding compounds |
| US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
| MXPA04004657A (es) * | 2001-11-14 | 2004-08-13 | Teva Pharma | Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion. |
| US20030144360A1 (en) | 2001-11-19 | 2003-07-31 | Allergan Sales, Inc. | Composition and method for modulating BAR/FXR receptor activity |
| WO2003080803A2 (en) | 2002-03-21 | 2003-10-02 | Smithkline Beecham Corporation | Methods of using farnesoid x receptor (fxr) agonists |
| CA2482195A1 (en) | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
| ITMI20021532A1 (it) | 2002-07-12 | 2004-01-12 | Roberto Pellicciari | Composti chimici |
| US7319109B2 (en) | 2002-11-22 | 2008-01-15 | Smith Kline Beecham Corporation | Farnesoid X receptor agonists |
| EP1696910A4 (en) | 2003-09-26 | 2009-12-09 | Smithkline Beecham Corp | COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROSIS |
| EP1568706A1 (en) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| WO2005092369A2 (en) * | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyethyl starch and erythropoietin |
| PT1734970E (pt) | 2004-03-12 | 2015-03-11 | Intercept Pharmaceuticals Inc | Tratamento de fibrose utilizando ligandos de rfx |
| BRPI0514269A (pt) * | 2004-08-10 | 2008-06-10 | Exelixis Inc | compostos heterocìclicos como agentes farmacêuticos |
| US20060252670A1 (en) * | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
| CA2814247C (en) | 2005-04-25 | 2016-01-19 | Genaera Corporation | Polymorphic and amorphous salt forms of squalamine dilactate |
| ITMI20050912A1 (it) * | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| JP2007077123A (ja) | 2005-09-16 | 2007-03-29 | Shiono Chemical Co Ltd | 非晶質セフジニル、その製造方法およびこれを含有する経口投与用医薬組成物 |
| WO2008002573A2 (en) | 2006-06-27 | 2008-01-03 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions |
| EP1894924A1 (en) * | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| CL2007003035A1 (es) * | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
| CA2928178C (en) | 2007-01-19 | 2019-09-10 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| EP1947108A1 (en) | 2007-01-19 | 2008-07-23 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| US8338628B2 (en) | 2007-08-28 | 2012-12-25 | City Of Hope | Method of synthesizing alkylated bile acid derivatives |
| BRPI0818813A2 (pt) * | 2007-11-15 | 2015-04-22 | Hoffmann La Roche | Compostos derivados de metil-benzimidazol, processo para a manufatura desses compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ ou profilático de enfermidades que são afetadas por moduladores de fxr e uso de tais compostos |
| EA020310B1 (ru) | 2008-07-30 | 2014-10-30 | Интерсепт Фармасьютикалз, Инк. | Модуляторы рецептора tgr5 и их применение |
| US20110190242A1 (en) * | 2008-09-23 | 2011-08-04 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of inflammatory disease |
| AU2009316566B9 (en) | 2008-11-19 | 2014-05-15 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and method of use thereof |
| JP5909774B2 (ja) | 2009-08-25 | 2016-04-27 | クィン ビル セラピューティクス インコーポレイテッド | 胆道疾患を治療するためのポリヒドロキシル化胆汁酸 |
| CN102121547B (zh) * | 2010-12-23 | 2013-01-16 | 拉卡萨安吉拉股份有限公司 | 用于管道接头的衬套和采用该衬套的管道接头 |
| CN102372757B (zh) | 2011-10-31 | 2013-01-16 | 安徽科宝生物工程有限公司 | 酯化法制备猪胆汁中鹅去氧胆酸的方法 |
| ES2822375T3 (es) | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
-
2013
- 2013-06-17 ES ES17202916T patent/ES2822375T3/es active Active
- 2013-06-17 SI SI201331813T patent/SI3336097T1/sl unknown
- 2013-06-17 PL PL17202916T patent/PL3336097T3/pl unknown
- 2013-06-17 CA CA2877122A patent/CA2877122C/en active Active
- 2013-06-17 NZ NZ703072A patent/NZ703072A/en unknown
- 2013-06-17 DK DK17202916.7T patent/DK3336097T3/da active
- 2013-06-17 SG SG11201408501UA patent/SG11201408501UA/en unknown
- 2013-06-17 EA EA201590040A patent/EA032347B1/ru unknown
- 2013-06-17 KR KR1020187020294A patent/KR20180083966A/ko not_active Ceased
- 2013-06-17 EP EP21195801.2A patent/EP3992201A1/en active Pending
- 2013-06-17 SG SG10201607230SA patent/SG10201607230SA/en unknown
- 2013-06-17 EA EA201990211A patent/EA201990211A1/ru unknown
- 2013-06-17 EP EP13733181.5A patent/EP2861613A1/en not_active Withdrawn
- 2013-06-17 CN CN202010196448.0A patent/CN111228278A/zh active Pending
- 2013-06-17 BR BR112014031828-0A patent/BR112014031828B1/pt active IP Right Grant
- 2013-06-17 AU AU2013277429A patent/AU2013277429B2/en active Active
- 2013-06-17 EP EP20190630.2A patent/EP3789394A1/en not_active Withdrawn
- 2013-06-17 CA CA3028207A patent/CA3028207A1/en not_active Abandoned
- 2013-06-17 EP EP17202916.7A patent/EP3336097B1/en active Active
- 2013-06-17 US US13/919,734 patent/US9238673B2/en active Active
- 2013-06-17 KR KR1020167034255A patent/KR101881245B1/ko not_active Expired - Fee Related
- 2013-06-17 KR KR1020197030749A patent/KR20190121871A/ko not_active Ceased
- 2013-06-17 CA CA3047776A patent/CA3047776C/en active Active
- 2013-06-17 HK HK15112051.4A patent/HK1211296A1/xx unknown
- 2013-06-17 NZ NZ719360A patent/NZ719360A/en not_active IP Right Cessation
- 2013-06-17 SG SG10201610434YA patent/SG10201610434YA/en unknown
- 2013-06-17 MX MX2014016062A patent/MX365059B/es active IP Right Grant
- 2013-06-17 CN CN201380043964.8A patent/CN104781272A/zh active Pending
- 2013-06-17 IN IN2561MUN2014 patent/IN2014MN02561A/en unknown
- 2013-06-17 KR KR1020157000110A patent/KR20150022974A/ko not_active Ceased
- 2013-06-17 JP JP2015518485A patent/JP2015521621A/ja active Pending
- 2013-06-17 WO PCT/US2013/046150 patent/WO2013192097A1/en not_active Ceased
- 2013-06-17 PT PT172029167T patent/PT3336097T/pt unknown
- 2013-06-17 NZ NZ734451A patent/NZ734451A/en not_active IP Right Cessation
- 2013-06-17 BR BR122016011808-8A patent/BR122016011808B1/pt active IP Right Grant
- 2013-06-18 TW TW102121547A patent/TWI673284B/zh not_active IP Right Cessation
-
2014
- 2014-12-14 IL IL236231A patent/IL236231A0/en active IP Right Grant
- 2014-12-19 MX MX2019005819A patent/MX2019005819A/es unknown
- 2014-12-19 CL CL2014003475A patent/CL2014003475A1/es unknown
- 2014-12-19 PH PH12014502835A patent/PH12014502835A1/en unknown
- 2014-12-30 CO CO14286414A patent/CO7240414A2/es unknown
-
2015
- 2015-07-30 CL CL2015002145A patent/CL2015002145A1/es unknown
- 2015-11-20 US US14/947,658 patent/US10047117B2/en active Active
- 2015-11-20 US US14/947,680 patent/US10155787B2/en active Active
- 2015-11-20 US US14/947,492 patent/US9732116B2/en active Active
- 2015-12-07 JP JP2015238204A patent/JP6527077B2/ja active Active
-
2016
- 2016-02-09 AU AU2016200832A patent/AU2016200832B2/en active Active
- 2016-12-16 JP JP2016244217A patent/JP2017075169A/ja not_active Withdrawn
-
2017
- 2017-04-25 US US15/496,398 patent/US10174073B2/en active Active
- 2017-06-15 AU AU2017204057A patent/AU2017204057B2/en active Active
-
2018
- 2018-03-04 IL IL257841A patent/IL257841A/en unknown
- 2018-07-23 JP JP2018137552A patent/JP2018172438A/ja not_active Withdrawn
- 2018-07-23 JP JP2018137553A patent/JP6877389B2/ja active Active
- 2018-08-26 IL IL261372A patent/IL261372A/en unknown
- 2018-10-05 AU AU2018241172A patent/AU2018241172B2/en active Active
- 2018-11-13 US US16/189,559 patent/US20190153020A1/en not_active Abandoned
-
2020
- 2020-04-06 AU AU2020202405A patent/AU2020202405A1/en not_active Abandoned
- 2020-04-13 JP JP2020071677A patent/JP6978544B2/ja active Active
-
2021
- 2021-01-06 US US17/142,870 patent/US20210395293A1/en not_active Abandoned
-
2023
- 2023-03-22 US US18/188,341 patent/US20230340010A1/en not_active Abandoned
-
2024
- 2024-02-08 US US18/436,527 patent/US20250011360A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2822375T3 (es) | Preparación de la forma no cristalina del ácido obeticólico | |
| US9982008B2 (en) | Preparation and uses of obeticholic acid | |
| WO2017111979A1 (en) | Polymorphic crystalline forms of obeticholic acid | |
| HK1254413A1 (en) | Polymorphic crystalline forms of obeticholic acid |